Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H Best,1 Amanda M Kong,2 David M Smith,2 Ibrahim Abbass,1 Margaret Michalska1 1Genentech, Inc., South San Francisco, CA, USA; 2IBM Watson Health, Cambridge, MA, USACorrespondence: Jennie H BestGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USATel +1 858 361-4937Email best.jennie@g...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-12-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/healthcare-costs-of-potential-glucocorticoid-associated-adverse-events-peer-reviewed-article-CEOR |
| _version_ | 1818334473048031232 |
|---|---|
| author | Best JH Kong AM Smith DM Abbass I Michalska M |
| author_facet | Best JH Kong AM Smith DM Abbass I Michalska M |
| author_sort | Best JH |
| collection | DOAJ |
| description | Jennie H Best,1 Amanda M Kong,2 David M Smith,2 Ibrahim Abbass,1 Margaret Michalska1 1Genentech, Inc., South San Francisco, CA, USA; 2IBM Watson Health, Cambridge, MA, USACorrespondence: Jennie H BestGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USATel +1 858 361-4937Email best.jennie@gene.comObjective: To quantify the healthcare expenditures associated with potential oral glucocorticoid (OGC)-related adverse events (AEs) in patients with giant cell arteritis (GCA).Methods: Patients with GCA and ≥ 1 OGC prescription fill between 2009 and 2014 were identified from the MarketScan Commercial and Medicare Supplemental claims databases. Patients were stratified into four groups based on cumulative OGC dose (> 0 to ≤ 2607 mg, > 2607 to ≤ 4800 mg, > 4800 to ≤ 7200 mg, and > 7200 mg) during the 1-year follow-up period; incidence of potential AEs and AE-related direct healthcare costs in USD were assessed. Association between the log of cumulative OGC dose and AE-related direct healthcare costs was evaluated, adjusting for baseline characteristics.Results: Of 1602 patients with GCA included, 69% were women; the mean age was 73 years. The mean cumulative OGC dose was 5806 mg during the 1-year follow-up; most exposure occurred in the first 6 months. The proportion of patients with potential OGC-related AEs was 36.5% overall and increased as cumulative dose increased (30.7%–45.3% across dose groups). Unadjusted mean AE-related costs for patients with an AE was USD $12,818. In the multivariable model including all patients, increasing OGC dose was associated with increasing AE-related healthcare costs (cost ratio, 1.38 [95% CI, 1.16–1.64] per 1-unit increase in log of cumulative OGC dose [P < 0.001]). Mean (median)-predicted AE costs for the dose groups were USD $4389 ($2749) for > 0 to ≤ 2607 mg, USD $5176 ($3009) for > 2607 to ≤ 4800 mg, USD $5576 ($3633) for > 4800 to ≤ 7200 mg, and USD $6609 ($4447) for > 7200 mg.Conclusion: In patients with GCA, OGC-related AEs increased with increasing cumulative OGC dose, resulting in increased healthcare costs. These results highlight the need for efficacious therapies that reduce the exposure to and potential risks associated with OGCs.Keywords: giant cell arteritis, glucocorticoid, adverse events, healthcare expenditures |
| first_indexed | 2024-12-13T14:08:05Z |
| format | Article |
| id | doaj.art-3def8477259b41f8908ac23ab1df508c |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-13T14:08:05Z |
| publishDate | 2019-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-3def8477259b41f8908ac23ab1df508c2022-12-21T23:42:34ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812019-12-01Volume 1179980750660Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell ArteritisBest JHKong AMSmith DMAbbass IMichalska MJennie H Best,1 Amanda M Kong,2 David M Smith,2 Ibrahim Abbass,1 Margaret Michalska1 1Genentech, Inc., South San Francisco, CA, USA; 2IBM Watson Health, Cambridge, MA, USACorrespondence: Jennie H BestGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USATel +1 858 361-4937Email best.jennie@gene.comObjective: To quantify the healthcare expenditures associated with potential oral glucocorticoid (OGC)-related adverse events (AEs) in patients with giant cell arteritis (GCA).Methods: Patients with GCA and ≥ 1 OGC prescription fill between 2009 and 2014 were identified from the MarketScan Commercial and Medicare Supplemental claims databases. Patients were stratified into four groups based on cumulative OGC dose (> 0 to ≤ 2607 mg, > 2607 to ≤ 4800 mg, > 4800 to ≤ 7200 mg, and > 7200 mg) during the 1-year follow-up period; incidence of potential AEs and AE-related direct healthcare costs in USD were assessed. Association between the log of cumulative OGC dose and AE-related direct healthcare costs was evaluated, adjusting for baseline characteristics.Results: Of 1602 patients with GCA included, 69% were women; the mean age was 73 years. The mean cumulative OGC dose was 5806 mg during the 1-year follow-up; most exposure occurred in the first 6 months. The proportion of patients with potential OGC-related AEs was 36.5% overall and increased as cumulative dose increased (30.7%–45.3% across dose groups). Unadjusted mean AE-related costs for patients with an AE was USD $12,818. In the multivariable model including all patients, increasing OGC dose was associated with increasing AE-related healthcare costs (cost ratio, 1.38 [95% CI, 1.16–1.64] per 1-unit increase in log of cumulative OGC dose [P < 0.001]). Mean (median)-predicted AE costs for the dose groups were USD $4389 ($2749) for > 0 to ≤ 2607 mg, USD $5176 ($3009) for > 2607 to ≤ 4800 mg, USD $5576 ($3633) for > 4800 to ≤ 7200 mg, and USD $6609 ($4447) for > 7200 mg.Conclusion: In patients with GCA, OGC-related AEs increased with increasing cumulative OGC dose, resulting in increased healthcare costs. These results highlight the need for efficacious therapies that reduce the exposure to and potential risks associated with OGCs.Keywords: giant cell arteritis, glucocorticoid, adverse events, healthcare expenditureshttps://www.dovepress.com/healthcare-costs-of-potential-glucocorticoid-associated-adverse-events-peer-reviewed-article-CEORgiant cell arteritisglucocorticoidadverse eventshealthcare expenditures |
| spellingShingle | Best JH Kong AM Smith DM Abbass I Michalska M Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis ClinicoEconomics and Outcomes Research giant cell arteritis glucocorticoid adverse events healthcare expenditures |
| title | Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis |
| title_full | Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis |
| title_fullStr | Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis |
| title_full_unstemmed | Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis |
| title_short | Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis |
| title_sort | healthcare costs of potential glucocorticoid associated adverse events in patients with giant cell arteritis |
| topic | giant cell arteritis glucocorticoid adverse events healthcare expenditures |
| url | https://www.dovepress.com/healthcare-costs-of-potential-glucocorticoid-associated-adverse-events-peer-reviewed-article-CEOR |
| work_keys_str_mv | AT bestjh healthcarecostsofpotentialglucocorticoidassociatedadverseeventsinpatientswithgiantcellarteritis AT kongam healthcarecostsofpotentialglucocorticoidassociatedadverseeventsinpatientswithgiantcellarteritis AT smithdm healthcarecostsofpotentialglucocorticoidassociatedadverseeventsinpatientswithgiantcellarteritis AT abbassi healthcarecostsofpotentialglucocorticoidassociatedadverseeventsinpatientswithgiantcellarteritis AT michalskam healthcarecostsofpotentialglucocorticoidassociatedadverseeventsinpatientswithgiantcellarteritis |